Abstract. Retinoic acid (RA) plays a critical role in embryonic development, growth, and reproduction. RA is synthesized from retinoids via oxidation processes, and the oxidation of retinal to RA is catalyzed by the retinaldehyde dehydrogenases (RALdhs). We previously reported that RALdh1 mRnA was expressed in the anterior pituitary glands of adult rats and suppressed by administration of 17β-estradiol in vivo. however, little is known about the mechanism regulating pituitary RALdh1 expression. In order to characterize the mechanism of estrogen-induced RALdh1 reduction, we examined the effect of 17β-estradiol on the regulation of pituitary RALDH1 gene expression and protein production both in vivo and in vitro. Using quantitative real-time PCR and immunoblot analysis, we found that levels of RALdh1 gene expression and protein production markedly decreased after 1-week treatment with 17β-estradiol in male rats. In immunohistochemical analysis, RALDH1-immunoreaction was observed in prolactin cells and folliculo-stellate cells. In 17β-estradiol-treated rats, RALdh1-immunoreactivity was lower in prolactin cells, but not in folliculo-stellate cells. treatment of isolated anterior pituitary cells with 17β-estradiol (10 -14 -10 -8 M) decreased expression of RALdh1 mRnA in a dose-dependent manner. estradiol-induced suppression of RALdh1 expression was completely blocked by the estrogen receptor (eR) antagonist ICI 182, 780. The ERα-selective agonist propylpyrazole triol (10 -8 M) mimicked the effect of 17β-estradiol on RALDH1 expression, but the ERβ-selective agonist diarylpropionitrile (10 -8 M) did not. these results strongly suggest that RALDH1 mRNA expression is suppressed by 17β-estradiol through ERα, and that estrogen regulates the expression of RALdh1 and production of RA in the anterior pituitary gland.
RETINOIC acid (RA) plays an essential role in the regulation of embryonic development, and in the maintenance of differentiation, growth, and reproduction in the adult organism [1] [2] [3] [4] . two sequential oxidative reactions generate RA from retinol. Retinol oxidation into retinal is carried out by several alcohol dehydrogenases or short-chain dehydrogenases/ reductases [5] . there are three retinaldehyde dehydrogenases (RALdh1, 2, 3) that catalyze the oxidation of retinal to RA [6] [7] [8] [9] [10] [11] . RALdhs display distinct expression patterns, and it is these different expression patterns that lead to the tissue-specific patterns of RA synthesis [12] .
In anterior pituitary gland, RA regulates gene expression of growth hormone [13] and thyroid-stimulating hormone β-subunit [14] , prolactin secretion [15] , and cell differentiation [16] . our previous work revealed that RALdh2 and RALdh3 mRnA were expressed in the embryonic pituitary gland of rat [17] , whereas RALdh1 mRnA was expressed in the pituitary gland of adult rat [18] . We speculated that RA may play a role as an autocrine and/or paracrine signaling molecule in this gland.
In order to understand modulation of RA generation in the pituitary, it is essential to understand the mechanism that regulates RALdh gene expression. We recently showed that RALdh1 mRnA level changes in estrus cycle and administration of 17β-estradiol suppresses RALdh1 expression in the anterior pituitary mL collagenase (nitta Gelatin, osaka, Japan) for 15 min at 37°C. thereafter, the pieces were incubated in the same solution containing 0.5 μg/mL DNase I (Boehringer-Mannheim, Mannheim, Germany) for 5 min at 37°C. After incubation in CMF-hBss containing 5 mM ethylenediaminetetraacetic acid (Wako Pure Chemicals, osaka, Japan) for 5 min at 37°C, the digest was washed with CMF-hBss. dispersed cells were suspended in CMF-hBss by pipette, passed through a 70-μm nylon mesh (Becton Dickinson Labware, Franklin Lakes, nJ, UsA), and then collected by centrifugation. the pellet was suspended in phenol redfree dMeM/F12 medium (Invitrogen) with 10% v/ v dextran-coated charcoal-treated fetal bovine serum (sigma, st Louis, Mo, UsA) and 1% v/v penicillinstreptomycin (Invitrogen). the cells (5 x 10 5 cells) were seeded in 24-well plates and then incubated at 37°C in a humidified atmosphere of 5% CO 2 and 95% air. the cells were exposed to a graded concentration of water-soluble 17β-estradiol (10 -14 -10 -8 M, sigma) for 72 h. In time-course experiments, the cells were exposed to 17β-estradiol (10 -8 M) for 1, 3, 6, or 24 h after 2-day culture. In addition, the cells were incubated for 24 h in either 17β-estradiol (10 -8 M), propylpyrazole triol (PPt, 10 -8 M, sigma), or diarylpropionitrile (dPn, 10 -8 M, tocris, ellisville, MI, UsA). some cells were pre-treated with the estrogen receptor antagonist ICI 182, 780 (10 -6 M, sigma) 1 h before and throughout the 17β-estradiol treatment for 24 h.
Quantification of RALDH1 mRNA levels by real-time reverse transcription (RT)-PCR
Quantitative real-time Rt-PCR was performed according to our previous report (Fujiwara et al. 2007b) . the PCR was performed by an ABI PRIsM 7900ht (Applied Biosystems, Foster City, CA, UsA) using gene-specific primers and sYBR Premix ex taq (takara Bio Inc., shiga, Japan) containing sYBR Green I. the following primers were used to amplify cdnA fragments of rat RALdh1: forward (5'-AtG GtC tAG CAG CAG GAG t -3') and reverse (5'-CCA GAC AtC ttG AAt CCA CCG AA -3'). For normalization, we also quantified β-actin using forward (5'-tGG CAC CAC ACt ttC tAC AAt GAG C-3') and reverse (5'-GGG tCA tCt ttt CAC GGt tGG-3') primers. gland of female rats [19] . our in vivo study indicated that estrogen is a candidate for regulator of RALdh1 expression in the pituitary, but the mechanisms that may be responsible for this effect are not understood. the actions of estrogen are thought to be mediated by the nuclear estrogen receptors (ERs), ERα and ERβ, which are able to regulate the transcriptional activity of target genes. to better understand the role of eRs in mediating the effect of estrogen on RALdh1 gene expression, we characterized the estrogen-responsiveness of RALdh1-producing cells and examined the effect of estrogen receptor agonists and an antagonist on RALdh1 expression in isolated anterior pituitary cells.
Materials and Methods

Animals
Male Wistar rats (aged 8-10 weeks) were purchased from Japan sLC, Inc. (shizuoka, Japan). s100b-GFP transgenic rats, which express green fluorescent protein (GFP) specifically in folliculo-stellate cells in the anterior pituitary, were donated by Professor Inoue of saitama University [20] . All animals were treated in accordance with the Guidelines for Animal experimentation of Jichi Medical University, which is based on the Guide for the Care and Use of Laboratory Animals of the national Academy of sciences, UsA. Rats were housed in a temperature-controlled room (22 ± 1°C) with a 12-hour light/12-hour dark cycle with illumination from 0700 h to 1900 h, and were given ad libitum access to conventional food and water. Bilateral castration was performed under sodium pentobarbital anesthesia (50 mg/kg i.p.), and castrated rats received subcutaneous implants of a silastic tube (inner diameter 2.0 mm, outer diameter 3.0 mm, length 20 mm; Kaneka Medix Co., Osaka, Japan) filled with 17β-estradiol (sigma Chemical Co., st. Louis, Mo, UsA).
Primary culture of anterior pituitary cells
Rats were perfused with Ca 2+ -and Mg 2+ -free hanks' Balanced salt solution (CMF-hBss) under deep sodium pentobarbital anesthesia. Anterior pituitary glands were excised and minced into pieces that were incubated in CMF-hBss containing 10 mg/mL trypsin (Invitrogen, Carlsbad, CA, UsA) and 2 mg/ served through a confocal laser microscope (FV1000; olympus, tokyo, Japan).
Western blot analysis
samples were extracted from pituitary glands by RIPA buffer (20 mM tris, 150 mM naCl, 2 mM edtA, 0.1% w/v sds, 1% v/v triton X-100, ph 7.5) with Protease Inhibitor Cocktail (Complete, edtAfree, Roche diagnostics Gmbh, Penzberg, Germany) and total protein was estimated by the Bradford assay (sigma). twenty micrograms of protein from each sample was electrophoresed on 12% sdspolyacrylamide gel and transferred to an Immobilon-P transfer membrane (Millipore, Bedford, MA, UsA). the membrane was blocked with 0.3% w/v skim milk (Yukijirushi Inc., tokyo, Japan) in tBst (50 mM tris, 100 mM naCl, 0.1% v/v tween 20, ph 7.4) for 1 h. After washing with tBst, the membrane was incubated overnight with rabbit polyclonal anti-RALdh1 antibody (1:10,000) or mouse anti-β-actin antibody (0.5 μg/mL, BioVision, Mountain View, CA, USA), diluted in Can Get signal solution (toyobo, osaka, Japan), followed by tBst washes, and incubated for 1 h with horseradish peroxidase (hRP)-labeled secondary antibodies (envision + system-hRP, dako, Glostrup, denmark). After washing with tBst, bands were visualized by 3,3'-diaminobenzidine. the membrane was scanned and densitometric analysis was performed with ImageJ software (nIh, Bethesda, Md, USA). The results were normalized with β-actin.
Statistical analysis
All results were presented as the mean ± s.e.M. statistical analysis was performed using AnoVA with Fisher's protected least significant difference test (statView 5.0 software, sAs Institute Inc. Cary, nC, UsA). differences between groups were considered to be statistically significant at a P-value of less than 0.05.
Results
Effect of estrogen on RALDH1 mRNA expression in pituitary glands of male rats
RALdh1 mRnA was detected in the pituitary glands of adult male rats by in situ hybridization using
Tissue preparation
For in situ hybridization and immunohistochemistry, rats were perfused with 4% formaldehyde in 0.05 M cacodylate buffer (ph 7.4) for 5 min through the left ventricle under deep sodium pentobarbital anesthesia. Pituitary glands were excised and immersed in the same fixative for 24 h at 4°C. the tissues were immersed for more than 2 days in cacodylate buffer containing 30% sucrose at 4°C. Frozen frontal sections of 8-μm thickness were obtained using a cryostat (CM3000; Leica Inc., Buffalo, nY, UsA) and mounted on glass slides.
In situ hybridization
In situ hybridization was performed according to our previous report [18] . hybridization of the RALdh1 antisense digoxigenin (dIG)-labeled cRnA probe (GeneBank accession no. BC061526, nucleotides 935-1485) was performed overnight at 60°C. Visualization of mRnA was performed with alkaline phosphatase-conjugated anti-dIG antibody (Roche diagnostics Gmbh, Penzberg, Germany) using 4-nitroblue tetrazolium chloride and 5-bromo-4-chloro-3-indolyl phosphate (Roche diagnostics Gmbh).
Immunohistochemistry the method for immunohistochemistry has been described elsewhere [21] . For RALdh1 immunohistochemistry, the sections were treated overnight at room temperature with a well-characterized antiRALdh1 antibody (raised in rabbit against the oligopeptide corresponding to the amino acids 330-341 of the rat RALdh1 and diluted to a ratio of 1:10,000) [21] , incubated with a biotin-conjugated secondary antibody (Vector Laboratories, Burlingame, CA, UsA), and then stained with an avidin-biotin-peroxidase reagent (Vectastain ABC Kit, Vector Laboratories) using 3,3'-diaminobenzidine (dojindo Laboratories, Kumamoto, Japan) as substrate. For fluorescence double-immunohistochemistry of RALdh1 and prolactin, the sections were incubated with RALdh1 rabbit antiserum and anti-rat prolactin mouse monoclonal IgG (1:2000 dilution; Chemicon International, temecula, CA, UsA), and then treated with Alexa Fluor 688-conjugated anti-rabbit goat IgG and Alexa Fluor 568-conjugated anti-mouse goat IgG (Invitrogen). sections were ob-mRnA in the pituitary gland significantly decreased after 17β-estradiol treatment (Fig. 1E) . RALDH1 mRNA expression in the presence of 17β-estradiol was 71% lower than that of the control rats.
Effect of estrogen on RALDH1 production in the pituitary
RALdh1-immunoreactive cells were observed a dIG-labeled antisense cRnA probe. RALdh1 mRnA-expressing cells were located in a wide range of the anterior pituitary gland, but mainly in the pars distalis ( Fig. 1A and B) . In the castrated male rats, only a few cells expressing RALdh1 mRnA were observed after 1-week treatment with 17β-estradiol ( Fig. 1C and  d) . RALdh1 mRnA level was quantified by realtime Rt-PCR. the relative concentration of RALdh1 RALDH1 production was lower in the 17β-estradioltreated animals (Fig. 2e) . We previously demonstrated that RALdh1 mRnA was expressed in prolactin cells and folliculo-stellate cells [18] . RALdh1 immunoreaction was also localized in these cells in male rats (Fig. 3A-F ). After treatment with 17β-estradiol for 1 week, RALdh1 immunoreactivity in prolactin cells was markedly lower; however, it was unchanged in the pars distalis of the male rats ( Fig. 2A and B) . however, the number of such cells was markedly lower after 1-week treatment with 17β-estradiol ( Fig. 2C  and d ). RALdh1-immunoreaction was also detected in the pituitary glands of male rats by Western blot analysis as an approximately 55-kda band, which conforms to the expected size of rat RALdh1 [22] (Fig.  2e ). When correlated with the mRnA expression, 
-treated rats (e). the upper panel shows
RALDH1 and the lower panel shows the β-actin loading control. Pooled data from 3 blots (mean ± S.E.M., n=3) were quantified by densitometry and normalized with β-actin. Groups that showed a statistically significant difference from the sham-operated group are indicated by an asterisk (*P < 0.01).
Fig. 3. double immunohistochemistry for RALdh1 and prolactin in the s100b-GFP transgenic rat.
Laser scanning confocal microscopic image of RALdh1-and prolactin-immunoreactive (ir) cells in the s100b-GFP transgenic rat. RALdh1 and prolactin were labeled by immunohistochemistry using Alexa Fluor 688 and Alexa Fluor 568 secondary antibody, respectively. emissions were recorded by photomultipliers for Alexa Fluor 688 (cyan pseudocolor) and Alexa Fluor 568 (red pseudocolor) fluorescent dyes, and GFP (green pseudocolor) in Fluoview imaging software. In untreated male rats, RALdh1-immunoreactivity was colocalized in both prolactin-ir cells (arrows) and folliculo-stellate cells, which were GFPexpressing cells (arrowheads) (A-D). However, after 1 week of treatment with 17β-estradiol (E 2 ), RALdh1-immunoreactivity in folliculo-stellate cells (arrowheads) was equal to that observed before treatment, whereas RALdh1-ir and prolactin-ir dou-
ble-positive cells were not observed (e-h). (A, G) RALdh1-ir images, (B, h) prolactin-ir images, (C, I) GFP images, (d, J)
RALdh1-immunoreactivity/prolactin-immunoreactivity/GFP-merged images, (e, K) RALdh1-immunoreactivity/prolactin-immunoreactivity-merged images, (F, L) RALDH1-immunoreactivity/GFP-merged images. Scale bar=10 μm.
or pituitary cell culture (Fig. 6A) . The ERα-selective agonist PPT significantly decreased RALDH1 mRNA levels, whereas the ERβ-selective agonist DPN had no effect (Fig. 6B) . these effects were observed at a concentration of 1 x 10 -8 M for each eR agonist, which is a concentration previously shown to selectively activate the ER-α and -β [23] . These results indicate that the effect of 17β-estradiol is mediated by the ERα subtype.
Discussion
RALdh1 is a dehydrogenase that generates RA in Xenopus [24] , chicken [25] , and mammals including human [6, 7, 26] . Rat RALdh1 catalyzes the oxidation of all-trans-retinal and 9-cis-retinal to all-trans-RA and 9-cis-RA, respectively [27, 28] . We reported previously that RALdh1 mRnA was expressed in the anterior pituitary gland of adult rat [18] . here, we also detected RALdh1-immunoreactive cells in this gland (Fig. 2) . these results suggest that RA is generated by RALdh1 in the adult anterior pituitary gland and may act locally on pituitary cells. in folliculo-stellate cells (Fig. 3G-L) .
In vitro effect of estrogen on isolated anterior pituitary cells
to determine whether estrogen directly affects RALdh1 expression in the pituitary gland, we investigated the effect of 17β-estradiol on RALDH1 mRNA level in isolated anterior pituitary cells. Quantitative real-time Rt-PCR showed that RALdh1 expression was significantly and dose-dependently lower after 17β-estradiol treatment for 72 h (Fig. 4) . RALdh1 mRnA expression after exposure to 10 M of 17β-estradiol decreased by 14%, 29%, 57%, and 64%, respectively, as compared to control. A timecourse analysis revealed that RALdh1 mRnA expression was significantly lower as early as 1 h after initiating treatment with 10 -8 M of 17β-estradiol (Fig. 5) .
Treatment with ER antagonist and agonists
Pretreatment with an eR antagonist-ICI 182, 780-completely abolished the inhibitory effect of 17β-estradiol on RALDH1 expression in the anteri- (Fig. 4 and  5) . this decrease in RALdh1 expression was observed in cells incubated with a 17β-estradiol concentration as low as 1 x 10 -14 M. Lieberman et al. [29] reported a dose-dependent increase in prolactin synthesis at physiological concentrations of estradiol (1 x 10 -11 -1 x 10 -6 M) in a rat pituitary cell culture. We previously reported that RALdh1 mRnA expression in the pituitary gland of ovariectomized rats was suppressed after a single subcutaneous injection of 17β-estradiol: mRnA expression in response to 0.01, 0.1, 1, 10, and 100 μg of 17β-estradiol decreased by 13%, our recent work has shown that RALdh1 mRnA expression level in the pituitary gland is lower in female than in male rats [19] . Moreover, we observed that RALdh1 mRnA expression was lower in female rats treated with 17β-estradiol [19] . In the present study, we confirmed that both RALDH1 mRNA transcription and protein production in the pituitary gland were lower after implantation of a 17β-estradiol-filled tube in male rats ( Fig. 1 and 2 ). our previous study showed that RALdh1 mRnA is expressed in prolactin cells and folliculo-stellate cells [18] . It is generally acknowledged that prolactin cells are a major target of estrogen in the pituitary. Prolactin gene expression and peptide synthesis are increased by estrogen [29, 30] . estrogen also induces c-fos [31] and galanin [32] transcription, and suppresses angiotensin II receptor [33] and transforming growth factor-β [34] , in prolactin cells. In the present study, we clearly demonstrated that RALdh1 immunoreactivity in prolactin cells was lower in rats treated with 17β-estradiol (Fig. 3) .
dopamine acts as a potent inhibitor of the secretion and synthesis of prolactin via interaction with the dopamine d2 receptor (d2R) [35] . RA induced the transcription of the d2R gene in MMQ, a rat pituitary cell line [36] . In addition, chronic administration of alltrans retinoic acid caused a decrease in serum prolactin levels in human [15] . thus RA may suppress the tors [41] [42] [43] [44] . differences in RALdh1 production between prolactin cells and folliculo-stellate cells may therefore be due to differential interaction with ERα-cofactors and/or modulators. In summary, both RALdh1 mRnA and protein are localized in the anterior pituitary gland of rat. In vivo estrogen treatment decreased RALdh1 production in the prolactin cells of male rats and, in cell culture, RALdh1 mRnA was lower in the presence of physiological concentrations of 17β-estradiol (1 x 10 -14 -10 -8
M). The 17β-estradiol-induced reduction of RALDH1 expression is mediated through ERα. We speculate that estrogen plays a role as a regulator of RALdh1 and controls production of RA in the pituitary gland.
38%, 53%, 64%, and 67%, respectively. Moreover, a time-course analysis of the effect of estradiol revealed that RALDH1 mRNA expression was significantly lower at 1 h after injection of 17β-estradiol (10 μg per rat) [19] . Our present results conform to those of our previous in vivo study. the rapid changes in RALdh1 expression that occur in the presence of physiological concentrations of estrogen highlight the potential significance of RALdh1 as a regulator of RA concentration in cells.
In the present study, we demonstrated that the effect of 17β-estradiol on RALDH1 expression was completely abolished by pretreatment with the eR antagonist ICI 182, 780 (Fig. 6) . Moreover, PPt-a potent, highly specific ERα agonist [37] -was capable of suppressing RALdh1 expression. In contrast, dPn-a highly potent agonist for ERβ with a 70-fold selectivity over ERα [38] -had no effect on RALDH1 expression. Taken together, our results show that 17β-estradiol inhibits RALdh1 expression via ERα in anterior pituitary cells. ERα has been identified in many anterior pituitary cell types, including prolactin cells and folliculo-stellate cells [39] . Interestingly, treatment with 17β-estradiol resulted in a reduction of RALdh1 immunoreactivity in prolactin cells, but not in folliculo-stellate cells (Fig. 3) . eR activation is modified by interaction with coactivators and cosuppressors [40] . 17β-estradiol has been reported to suppress the transcription of other genes through eR, and this may involve cofactors or transcription fac-
